Price T Rowe Associates Inc. MD Has $276.40 Million Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Price T Rowe Associates Inc. MD grew its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 3.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 6,870,333 shares of the company’s stock after acquiring an additional 224,859 shares during the period. Price T Rowe Associates Inc. MD owned 10.61% of Kymera Therapeutics worth $276,395,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of KYMR. Wellington Management Group LLP raised its stake in Kymera Therapeutics by 14.9% during the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock worth $213,514,000 after buying an additional 688,967 shares during the last quarter. Avoro Capital Advisors LLC raised its position in shares of Kymera Therapeutics by 14.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock worth $207,184,000 after purchasing an additional 650,000 shares during the period. Vanguard Group Inc. raised its holdings in Kymera Therapeutics by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company’s stock worth $196,617,000 after buying an additional 133,546 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Kymera Therapeutics by 5.0% in the 4th quarter. Geode Capital Management LLC now owns 1,105,487 shares of the company’s stock worth $44,484,000 after acquiring an additional 52,263 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Kymera Therapeutics by 5.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company’s stock valued at $15,577,000 after acquiring an additional 20,346 shares in the last quarter.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. HC Wainwright boosted their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Friday, December 27th. Stephens reaffirmed an “overweight” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Finally, Citigroup began coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They set a “buy” rating and a $52.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.36.

Insiders Place Their Bets

In related news, CFO Bruce N. Jacobs sold 7,035 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the transaction, the chief financial officer now owns 201,886 shares of the company’s stock, valued at approximately $6,147,428.70. This trade represents a 3.37 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Jeremy G. Chadwick sold 1,383 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $42,112.35. Following the transaction, the chief operating officer now owns 67,800 shares in the company, valued at $2,064,510. This trade represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,659 shares of company stock worth $324,567 in the last three months. 15.82% of the stock is owned by company insiders.

Kymera Therapeutics Stock Performance

NASDAQ KYMR opened at $33.26 on Friday. The stock has a 50-day moving average of $29.89 and a 200 day moving average of $38.61. Kymera Therapeutics, Inc. has a one year low of $19.45 and a one year high of $53.27. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of -14.21 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. On average, equities analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.